Press release
United Therapeutics Corporation Reports Second Quarter 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second quarter of 2023.\n\n\n“This quarter we drove record revenue from our foundational commercial business. Next year we expect data from our innovative clinical pipeline. All this while we march forward with our revolutionary organ manufacturing programs,” said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “We believe there is no other biotech with our combination of relentless focus, near-term commercial growth, and clinical potential.”\n\n\nMichael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, “Our fifth straight quarter of record revenue was driven by continued traction for Tyvaso in pulmonary hypertension associated with interstitial lung disease, along with strong fundamentals for our other products in pulmonary arterial hypertension and neuroblastoma.”\n\n\nSecond Quarter 2024 Financial Results\n\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n\n \n\n\n\n\n\n\nThree Months Ended\nJune 30,\n\n\n\n\n\n\n \n\n\n\n\n\n\nDollar\nChange\n\n\n\n\n\n\n \n\n\n\n\n\n\nPercentage Change\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2024\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2023\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nTotal revenues\n\n\n\n\n\n\n$\n\n\n\n\n\n\n714.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n596.5\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n118.4\n\n\n\n\n\n\n \n\n\n\n\n\n\n20\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNet income\n\n\n\n\n\n\n$\n\n\n\n\n\n\n278.1\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n259.2\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n18.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n7\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNet income, per basic share\n\n\n\n\n\n\n$\n\n\n\n\n\n\n6.26\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n5.53\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n0.73\n\n\n\n\n\n\n \n\n\n\n\n\n\n13\n\n\n\n\n\n\n%\n\n\n\n\n\...